Enliven Therapeutics, Inc. (NASDAQ:ELVN) CEO Samuel Kintz Sells 16,710 Shares

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CEO Samuel Kintz sold 16,710 shares of Enliven Therapeutics stock in a transaction that occurred on Wednesday, October 9th. The stock was sold at an average price of $28.15, for a total transaction of $470,386.50. Following the completion of the transaction, the chief executive officer now owns 1,003,816 shares of the company’s stock, valued at $28,257,420.40. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Samuel Kintz also recently made the following trade(s):

• On Monday, October 7th, Samuel Kintz sold 2,730 shares of Enliven Therapeutics stock. The stock was sold at an average price of $27.50, for a total transaction of $75,075.00.
• On Friday, October 4th, Samuel Kintz sold 12,206 shares of Enliven Therapeutics stock. The stock was sold at an average price of $27.51, for a total transaction of $335,787.06.
• On Tuesday, October 1st, Samuel Kintz sold 526 shares of Enliven Therapeutics stock. The stock was sold at an average price of $27.54, for a total transaction of $14,486.04.
• On Monday, August 26th, Samuel Kintz sold 12,000 shares of Enliven Therapeutics stock. The stock was sold at an average price of $22.89, for a total transaction of $274,680.00.
• On Wednesday, July 31st, Samuel Kintz sold 2,270 shares of Enliven Therapeutics stock. The stock was sold at an average price of $27.56, for a total transaction of $62,561.20.
• On Thursday, July 25th, Samuel Kintz sold 12,000 shares of Enliven Therapeutics stock. The stock was sold at an average price of $24.92, for a total transaction of $299,040.00.

Enliven Therapeutics Price Performance

ELVN stock opened at $27.91 on Friday. The company has a fifty day moving average price of $23.34 and a 200 day moving average price of $22.22. Enliven Therapeutics, Inc. has a 12 month low of $9.80 and a 12 month high of $28.62. The company has a market cap of $1.32 billion, a price-to-earnings ratio of -14.46 and a beta of 1.10.

Enliven Therapeutics (NASDAQ:ELVN) last released its quarterly earnings results on Tuesday, August 13th. The company reported ($0.41) EPS for the quarter, beating the consensus estimate of ($0.58) by $0.17. As a group, analysts anticipate that Enliven Therapeutics, Inc. will post -1.98 earnings per share for the current year.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a “buy” rating and set a $37.00 price objective on shares of Enliven Therapeutics in a research report on Tuesday, October 1st.

Institutional Trading of Enliven Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the business. Quest Partners LLC raised its position in Enliven Therapeutics by 87.3% in the 2nd quarter. Quest Partners LLC now owns 1,592 shares of the company’s stock valued at $37,000 after purchasing an additional 742 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its stake in Enliven Therapeutics by 67.0% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 7,952 shares of the company’s stock valued at $140,000 after buying an additional 3,189 shares during the period. American Century Companies Inc. increased its stake in Enliven Therapeutics by 44.7% in the 2nd quarter. American Century Companies Inc. now owns 27,651 shares of the company’s stock valued at $646,000 after buying an additional 8,540 shares during the period. EntryPoint Capital LLC acquired a new position in Enliven Therapeutics in the 1st quarter valued at $167,000. Finally, SG Americas Securities LLC acquired a new position in Enliven Therapeutics in the 3rd quarter valued at $256,000. Hedge funds and other institutional investors own 95.08% of the company’s stock.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.